Catalepsy
Haloperidol
Dopamine Antagonists
Antipsychotic Agents
Thioxanthenes
Flupenthixol
Biperiden
Clozapine
Receptors, Dopamine D2
Apomorphine
Stereotyped Behavior
Biogenic Amines
Serotonin 5-HT1 Receptor Agonists
Anti-Dyskinesia Agents
Aprindine
Phenmetrazine
Basal Ganglia Diseases
Neurotensin
Dronabinol
Receptors, Neurotensin
Raclopride
Synergistic interactions between ampakines and antipsychotic drugs. (1/188)
Tests were made for interactions between antipsychotic drugs and compounds that enhance synaptic currents mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors ("ampakines"). Typical and atypical antipsychotic drugs decreased methamphetamine-induced hyperactivity in rats; the effects of near or even subthreshold doses of the antipsychotics were greatly enhanced by the ampakines. Interactions between the ampakine CX516 and low doses of different antipsychotics were generally additive and often synergistic. The ampakine did not exacerbate neuroleptic-induced catalepsy, indicating that the interaction between the different pharmacological classes was selective. These results suggest that positive modulators of cortical glutamatergic systems may be useful adjuncts in treating schizophrenia. (+info)Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. (2/188)
Atypical neuroleptics produce fewer extrapyramidal side-effects (EPS) than typical neuroleptics. The pharmacological profile of atypical neuroleptics is that they have equivalent or higher antagonist affinity for 5-HT2 than for dopamine D2 receptors. Our aim was to identify which 5-HT2 receptor contributed to the atypical profile. Catalepsy was defined as rats remaining immobile over a horizontal metal bar for at least 30 s, 90 min after dosing. Radioligand binding assays were carried out with homogenates of human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors expressed in Human Embryo Kidney (HEK293) cells. Haloperidol (1.13 mg kg(-1) i.p.) induced catalepsy in all experiments. The selective 5-HT2C/2B receptor antagonist, SB-228357 (0.32-10 mg kg(-1) p.o.) significantly reversed haloperidol-induced catalepsy whereas the 5-HT2A and 5-HT2B receptor antagonists, MDL-100907 (0.003-0.1 mg kg(-1) p.o.) and SB-215505 (0.1-3.2 mg kg(-1) p.o.) respectively did not reverse haloperidol-induced catalepsy. The data suggest a role for 5-HT2C receptors in the anticataleptic action of SB-228357. (+info)In vivo effects of new inhibitors of catechol-O-methyl transferase. (3/188)
1. The effects of two new synthetic compounds showing in vitro catechol-O-methyl transferase (COMT) inhibitor properties were studied in vivo and compared with the effects of nitecapone and Ro-41-0960. 2. QO IA (3-(3-hydroxy-4-methoxy-5-nitrobenzylidene)-2,4-pentanedione), QO IIR ([2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone), nitecapone and Ro-41-0960 (30 mg kg(-1), i.p.) were given to reserpinized rats 1 h before the administration of L-DOPA/carbidopa (LD/CD, 50:50 mg kg(-1), i.p.). Locomotor activity was assessed 1 h later. All the COMT inhibitors (COMTI), with the exception of QO IA, markedly potentiated LD/CD reversal of reserpine-induced akinesia. Similar results were obtained when the COMTI were coadministered with LD/CD. The effect of compound QO IIR was dose-dependent (7.5-30 mg kg(-1), i.p.). 3. The COMTI (30 mg kg(-1), i.p.) potentiated LD/CD reversal of both catalepsy and hypothermia of reserpinized mice. 4. QO IIR, nitecapone and Ro-41-0960 (30 mg kg(-1), i.p.) reduced striatal 3-methyl-DOPA (3-OMD) levels and increased dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) levels. Compound QO IA was devoid of any effect on striatal amine levels. In contrast to the other inhibitors, Ro-41-0961 reduced HVA levels as well. The effect of QO IIR on striatal amine levels was dose-dependent (7.5-60 mg kg(-1), i.p.) 5. These results suggest that the new compound QO IIR is an effective peripherally acting COMT inhibitor in vivo. (+info)Effects of rubidium on behavioral responses to methamphetamine and tetrabenazine. (4/188)
Different groups of mice were injected subcutaneously every other day with rubidium chloride at three doses (0.41(50), 1.23(150) and 3.69(450) meq/kg (mg/kg)) or with saline as a control for a period of 2-3 weeks. Rubidium administered acutely did not affect spontaneous locomotor activities, while it tended to increase the activities when administered repeatedly though the increase was not statistically significant. The methamphetamine-induced hyperlocomotor activities were potentiated in the rubidium groups as compared with those in the saline group, this effect of ribidium being increased with prolongation of repeated administrations. Monotonic decreases in ambulation after tetrabenazine were not significantly affected in the rubidium-treated animals though the decreases were sometimes preceded by slight increases and recovery from the decrement tended to be more rapid. After tetrabenazine in the rubidium-treated groups, incidences of catalepsy were increased and jumping behavior and Straub tail responses occurred in a few cases. The results suggest that rubidium potentiates the excitatory action of methamphetamine on spontaneous locomotor activities, as contrasted with inhibitory influence of lithium. (+info)Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14. (5/188)
Previous studies have established that neuroleptic-induced catalepsy in mice is a highly heritable trait. The current study focuses on the detection of quantitative trait loci (QTL) for haloperidol-induced catalepsy in a BALB/cJ x LP/J F(2) intercross. One thousand thirty-seven F(2) animals were phenotyped and divided into four categories: very responsive (RR), responsive, nonresponsive, and very nonresponsive (NN). The RR and NN phenotypes comprised approximately 18% each of the total and differed in their haloperidol sensitivity by >10-fold. Sex differed significantly between the NN and RR groups (chi(2) = 14.0; p <.0002); females comprised 58% of the RR individuals but only 38% of the NN individuals. The difference between the extreme phenotypes in the number of piebald animals was highly significant (chi(2) = 30, p <. 00001). Eight percent of the RR individuals were piebald compared with 30% of the NN individuals. A genome wide scan confirmed the presence of a QTL (peak LOD = 6.4) on chromosome 14 near the piebald (Ednrb) and 5-hydroxytryptamine(2A) (Htr2a) loci. Although the parental BALB/cJ and LP/J strains differed significantly in striatal 5-hydroxytryptamine(2A) receptor binding, no marked differences were detected between the phenotypic extremes. A second QTL was detected on chromosome 14 (peak LOD = 6.9), which was located more proximally and included the Chat locus. No QTLs were detected on chromosomes 1 and 9, thus differentiating this cross from previous results obtained for a C57BL/6J x DBA/2J intercross. (+info)Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. (6/188)
Clozapine exerts superior clinical efficacy and markedly enhances cortical dopamine output compared with classical antipsychotic drugs. Here the alpha2 adrenoceptor antagonist idazoxan was administered to rats alone or in combination with the D2/3 dopamine receptor antagonist raclopride. Dopamine efflux in the medial prefrontal cortex and conditioned avoidance responding were analyzed. Idazoxan selectively potentiated the cortical output of dopamine and augmented the suppression of conditioned avoidance responding induced by raclopride. These results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action. (+info)Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice. (7/188)
The cataleptic behavior induced by the dopamine D1 antagonist SCH 23390 (SCH) has proven to be a useful assay for investigating the sensitivity of D1-like dopamine receptor-mediated effects during chronic drug administration. A fundamental flaw in most of these studies may be the involvement of the "repeated measures effect," a behavioral phenomenon well demonstrated for neuroleptic-induced catalepsy but not yet investigated for dopamine D1 antagonists. In this study, mice exposed for various sessions to the bar test presented a strong sensitization to the cataleptic behavior induced by repeated SCH treatment. Conversely, single tested animals exhibited a trend toward decreased catalepsy after repeated SCH treatment, which was in line with the development of a D1-like dopamine receptor supersensitivity suggested by an increase in SKF 38393-induced grooming behavior. Surprisingly, a challenge intraperitoneal saline injection increased the cataleptic behavior of single tested mice after long-term SCH treatment. This "injection-conditioned catalepsy" was also observed after repeated treatment with the dopamine D2 antagonists, haloperidol and metoclopramide. While these findings seem to explain some important contradictory data in the literature, they provide a new and simple animal model of the placebo effect. (+info)Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. (8/188)
Acute blockade of dopamine D(2) receptors by the typical antipsychotic drug haloperidol leads to alterations in neuronal gene expression and behavior. In the dorsolateral striatum, the levels of mRNA for the immediate-early gene c-fos and the neuropeptide gene neurotensin/neuromedin N (NT/N) are significantly increased by haloperidol. An acute behavioral response to haloperidol is catalepsy, considered to be a rodent correlate of some of the immediate extrapyramidal motor side effects seen in humans. Several lines of evidence suggest a link between neurotensin induction in the dorsolateral striatum and catalepsy. We hypothesize that both striatal gene induction and catalepsy elicited by haloperidol arise from the combined effect of excitatory adenosinergic and glutamatergic inputs acting at adenosine A(2A) and N-methyl-D-aspartate (NMDA) receptors, respectively. In agreement with our previous reports, adenosine antagonists reduced haloperidol-induced c-fos and neurotensin gene expression as well as catalepsy. In agreement with other reports, the noncompetitive NMDA receptor antagonist MK-801 also reduced gene expression and catalepsy in response to haloperidol. The competitive NMDA receptor antagonist LY235959 decreased haloperidol-induced catalepsy. We show here that blocking both A(2A) and NMDA receptors simultaneously in conjunction with haloperidol resulted in a combined effect on gene expression and behavior that was greater than that for block of either receptor alone. Both c-fos and NT/N mRNA levels were reduced, and catalepsy was completely abolished. These results indicate that the haloperidol-induced increases in c-fos and NT gene expression in the dorsolateral striatum and catalepsy are driven largely by adenosine and glutamatergic inputs acting at A(2A) and NMDA receptors. (+info)Catalepsy is a medical condition characterized by a trance-like state, with reduced sensitivity to pain and external stimuli, muscular rigidity, and fixed postures. In this state, the person's body may maintain any position in which it is placed for a long time, and there is often a decreased responsiveness to social cues or communication attempts.
Catalepsy can be a symptom of various medical conditions, including neurological disorders such as epilepsy, Parkinson's disease, or brain injuries. It can also occur in the context of mental health disorders, such as severe depression, catatonic schizophrenia, or dissociative identity disorder.
In some cases, catalepsy may be induced intentionally through hypnosis or other forms of altered consciousness practices. However, when it occurs spontaneously or as a symptom of an underlying medical condition, it can be a serious concern and requires medical evaluation and treatment.
Haloperidol is an antipsychotic medication, which is primarily used to treat schizophrenia and symptoms of psychosis, such as delusions, hallucinations, paranoia, or disordered thought. It may also be used to manage Tourette's disorder, tics, agitation, aggression, and hyperactivity in children with developmental disorders.
Haloperidol works by blocking the action of dopamine, a neurotransmitter in the brain, which helps to regulate mood and behavior. It is available in various forms, including tablets, liquid, and injectable solutions. The medication can cause side effects such as drowsiness, restlessness, muscle stiffness, and uncontrolled movements. In rare cases, it may also lead to more serious neurological side effects.
As with any medication, haloperidol should be taken under the supervision of a healthcare provider, who will consider the individual's medical history, current medications, and other factors before prescribing it.
Dopamine antagonists are a class of drugs that block the action of dopamine, a neurotransmitter in the brain associated with various functions including movement, motivation, and emotion. These drugs work by binding to dopamine receptors and preventing dopamine from attaching to them, which can help to reduce the symptoms of certain medical conditions such as schizophrenia, bipolar disorder, and gastroesophageal reflux disease (GERD).
There are several types of dopamine antagonists, including:
1. Typical antipsychotics: These drugs are primarily used to treat psychosis, including schizophrenia and delusional disorders. Examples include haloperidol, chlorpromazine, and fluphenazine.
2. Atypical antipsychotics: These drugs are also used to treat psychosis but have fewer side effects than typical antipsychotics. They may also be used to treat bipolar disorder and depression. Examples include risperidone, olanzapine, and quetiapine.
3. Antiemetics: These drugs are used to treat nausea and vomiting. Examples include metoclopramide and prochlorperazine.
4. Dopamine agonists: While not technically dopamine antagonists, these drugs work by stimulating dopamine receptors and can be used to treat conditions such as Parkinson's disease. However, they can also have the opposite effect and block dopamine receptors in high doses, making them functionally similar to dopamine antagonists.
Common side effects of dopamine antagonists include sedation, weight gain, and movement disorders such as tardive dyskinesia. It's important to use these drugs under the close supervision of a healthcare provider to monitor for side effects and adjust the dosage as needed.
Antipsychotic agents are a class of medications used to manage and treat psychosis, which includes symptoms such as delusions, hallucinations, paranoia, disordered thought processes, and agitated behavior. These drugs work by blocking the action of dopamine, a neurotransmitter in the brain that is believed to play a role in the development of psychotic symptoms. Antipsychotics can be broadly divided into two categories: first-generation antipsychotics (also known as typical antipsychotics) and second-generation antipsychotics (also known as atypical antipsychotics).
First-generation antipsychotics, such as chlorpromazine, haloperidol, and fluphenazine, were developed in the 1950s and have been widely used for several decades. They are generally effective in reducing positive symptoms of psychosis (such as hallucinations and delusions) but can cause significant side effects, including extrapyramidal symptoms (EPS), such as rigidity, tremors, and involuntary movements, as well as weight gain, sedation, and orthostatic hypotension.
Second-generation antipsychotics, such as clozapine, risperidone, olanzapine, quetiapine, and aripiprazole, were developed more recently and are considered to have a more favorable side effect profile than first-generation antipsychotics. They are generally effective in reducing both positive and negative symptoms of psychosis (such as apathy, anhedonia, and social withdrawal) and cause fewer EPS. However, they can still cause significant weight gain, metabolic disturbances, and sedation.
Antipsychotic agents are used to treat various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder with psychotic features, delusional disorder, and other conditions that involve psychosis or agitation. They can be administered orally, intramuscularly, or via long-acting injectable formulations. The choice of antipsychotic agent depends on the individual patient's needs, preferences, and response to treatment, as well as the potential for side effects. Regular monitoring of patients taking antipsychotics is essential to ensure their safety and effectiveness.
Thioxanthenes are a group of heterocyclic organic compounds that contain a thioxanthene nucleus, which is a six-membered ring containing five carbon atoms and one sulfur atom. Thioxanthenes are structurally related to phenothiazines and have been used in the synthesis of various pharmaceutical drugs, particularly antipsychotic medications.
In medical terms, thioxanthenes refer to a class of antipsychotic drugs that are used to treat various psychiatric disorders such as schizophrenia and related conditions. These drugs work by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis such as hallucinations, delusions, and disordered thinking.
Some examples of thioxanthene antipsychotics include chlorprothixene, thiothixene, and flupenthixol. Like other antipsychotic medications, thioxanthenes can have side effects such as extrapyramidal symptoms (EPS), which are movement disorders that can cause stiffness, tremors, or spasms. Other potential side effects of thioxanthenes may include sedation, orthostatic hypotension, and weight gain.
Flupenthixol is an antipsychotic medication that belongs to the chemical class of diphenylbutylpiperidines. It has potent dopamine D2 receptor blocking activity and moderate serotonin 5-HT2A receptor blocking activity, which makes it effective in managing various psychiatric disorders.
Flupenthixol is primarily used for the treatment of chronic schizophrenia and other related psychotic disorders. It can help alleviate symptoms such as hallucinations, delusions, thought disorders, and hostility. Additionally, flupenthixol may also be used off-label to manage depression, anxiety, and aggression in individuals with developmental disabilities or dementia.
The medication is available in two forms: immediate-release tablets (Flupenthixol decanoate) for short-term use and a long-acting depot injection (Flupenthixol dihydrochloride) that can be administered every 2-4 weeks, providing sustained therapeutic levels of the drug.
As with any medication, flupenthixol should be used under the close supervision of a healthcare professional due to potential side effects and interactions with other drugs. Common side effects include extrapyramidal symptoms (involuntary muscle movements), sedation, weight gain, and sexual dysfunction. Rare but serious adverse reactions may include neuroleptic malignant syndrome, tardive dyskinesia, and metabolic disorders.
Biperiden is an anticholinergic drug, which is primarily used to treat symptoms of Parkinson's disease such as stiffness, tremors, spasms, and poor muscle control. It works by blocking the action of a certain natural substance (acetylcholine) in the body. Biperiden can also be used to treat related conditions such as drooling, loss of bladder control, and movement disorders caused by certain medications.
Biperiden may also be used for purposes not listed in its medical product label, as determined by a doctor. It is available in immediate-release and extended-release tablets and oral solution forms. Common side effects include dizziness, drowsiness, dry mouth, blurred vision, and difficulty urinating. Serious side effects are rare but may include hallucinations, irregular heartbeat, and mental/mood changes.
It is important to follow the instructions of a healthcare professional when taking biperiden, as it can interact with other medications and have potentially serious side effects if not used properly.
Clozapine is an atypical antipsychotic medication that is primarily used to treat schizophrenia in patients who have not responded to other antipsychotic treatments. It is also used off-label for the treatment of severe aggression, suicidal ideation, and self-injurious behavior in individuals with developmental disorders.
Clozapine works by blocking dopamine receptors in the brain, particularly the D4 receptor, which is thought to be involved in the development of schizophrenia. It also has a strong affinity for serotonin receptors, which contributes to its unique therapeutic profile.
Clozapine is considered a medication of last resort due to its potential side effects, which can include agranulocytosis (a severe decrease in white blood cell count), myocarditis (inflammation of the heart muscle), seizures, orthostatic hypotension (low blood pressure upon standing), and weight gain. Because of these risks, patients taking clozapine must undergo regular monitoring of their blood counts and other vital signs.
Despite its potential side effects, clozapine is often effective in treating treatment-resistant schizophrenia and has been shown to reduce the risk of suicide in some patients. It is available in tablet and orally disintegrating tablet formulations.
Dopamine D2 receptor is a type of metabotropic G protein-coupled receptor that binds to the neurotransmitter dopamine. It is one of five subtypes of dopamine receptors (D1-D5) and is encoded by the gene DRD2. The activation of D2 receptors leads to a decrease in the activity of adenylyl cyclase, which results in reduced levels of cAMP and modulation of ion channels.
D2 receptors are widely distributed throughout the central nervous system (CNS) and play important roles in various physiological functions, including motor control, reward processing, emotion regulation, and cognition. They are also involved in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, drug addiction, and Tourette syndrome.
D2 receptors have two main subtypes: D2 short (D2S) and D2 long (D2L). The D2S subtype is primarily located in the presynaptic terminals and functions as an autoreceptor that regulates dopamine release, while the D2L subtype is mainly found in the postsynaptic neurons and modulates intracellular signaling pathways.
Antipsychotic drugs, which are used to treat schizophrenia and other psychiatric disorders, work by blocking D2 receptors. However, excessive blockade of these receptors can lead to side effects such as extrapyramidal symptoms (EPS), tardive dyskinesia, and hyperprolactinemia. Therefore, the development of drugs that selectively target specific subtypes of dopamine receptors is an active area of research in the field of neuropsychopharmacology.
Apomorphine is a non-selective dopamine receptor agonist, which means that it activates dopamine receptors in the brain. It has a high affinity for D1 and D2 dopamine receptors and is used medically to treat Parkinson's disease, particularly in cases of severe or intractable motor fluctuations.
Apomorphine can be administered subcutaneously (under the skin) as a solution or as a sublingual (under the tongue) film. It works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease such as stiffness, tremors, and difficulty with movement.
In addition to its use in Parkinson's disease, apomorphine has also been investigated for its potential therapeutic benefits in other neurological disorders, including alcohol use disorder and drug addiction. However, more research is needed to establish its safety and efficacy in these conditions.
Stereotyped behavior, in the context of medicine and psychology, refers to repetitive, rigid, and invariant patterns of behavior or movements that are purposeless and often non-functional. These behaviors are not goal-directed or spontaneous and typically do not change in response to environmental changes or social interactions.
Stereotypies can include a wide range of motor behaviors such as hand flapping, rocking, head banging, body spinning, self-biting, or complex sequences of movements. They are often seen in individuals with developmental disabilities, intellectual disabilities, autism spectrum disorder, and some mental health conditions.
Stereotyped behaviors can also be a result of substance abuse, neurological disorders, or brain injuries. In some cases, these behaviors may serve as a self-soothing mechanism or a way to cope with stress, anxiety, or boredom. However, they can also interfere with daily functioning and social interactions, and in severe cases, may cause physical harm to the individual.
Biogenic amines are organic compounds that are derived from the metabolic pathways of various biological organisms, including humans. They are formed by the decarboxylation of amino acids, which are the building blocks of proteins. Some examples of biogenic amines include histamine, serotonin, dopamine, and tyramine.
Histamine is a biogenic amine that plays an important role in the immune system's response to foreign invaders, such as allergens. It is also involved in regulating stomach acid production and sleep-wake cycles. Serotonin is another biogenic amine that acts as a neurotransmitter, transmitting signals between nerve cells in the brain. It is involved in regulating mood, appetite, and sleep.
Dopamine is a biogenic amine that functions as a neurotransmitter and is involved in reward and pleasure pathways in the brain. Tyramine is a biogenic amine that is found in certain foods, such as aged cheeses and fermented soy products. It can cause an increase in blood pressure when consumed in large quantities.
Biogenic amines can have various effects on the body, depending on their type and concentration. In general, they play important roles in many physiological processes, but high levels of certain biogenic amines can be harmful and may cause symptoms such as headache, nausea, and hypertension.
Serotonin 5-HT1 Receptor Agonists are a class of compounds that bind to and activate the serotonin 5-HT1 receptors, which are G protein-coupled receptors found in the central and peripheral nervous systems. These receptors play important roles in regulating various physiological functions, including neurotransmission, vasoconstriction, and hormone secretion.
Serotonin 5-HT1 Receptor Agonists are used in medical therapy to treat a variety of conditions, such as migraines, cluster headaches, depression, anxiety, and insomnia. Some examples of Serotonin 5-HT1 Receptor Agonists include sumatriptan, rizatriptan, zolmitriptan, naratriptan, and frovatriptan, which are used to treat migraines and cluster headaches by selectively activating the 5-HT1B/1D receptors in cranial blood vessels and sensory nerves.
Other Serotonin 5-HT1 Receptor Agonists, such as buspirone, are used to treat anxiety disorders and depression by acting on the 5-HT1A receptors in the brain. These drugs work by increasing serotonergic neurotransmission, which helps to regulate mood, cognition, and behavior.
Overall, Serotonin 5-HT1 Receptor Agonists are a valuable class of drugs that have shown efficacy in treating various neurological and psychiatric conditions. However, like all medications, they can have side effects and potential drug interactions, so it is important to use them under the guidance of a healthcare professional.
Anti-dyskinetic agents are a class of medications that are used to treat or manage dyskinesias, which are involuntary movements or abnormal muscle contractions. These medications work by blocking or reducing the activity of dopamine, a neurotransmitter in the brain that is involved in movement control.
Dyskinetic symptoms can occur as a side effect of long-term use of levodopa therapy in patients with Parkinson's disease. Anti-dyskinetic agents such as amantadine, anticholinergics, and dopamine agonists may be used to manage these symptoms.
Amantadine works by increasing the release of dopamine and blocking its reuptake, which can help reduce dyskinesias. Anticholinergic medications such as trihexyphenidyl and benztropine work by blocking the action of acetylcholine, another neurotransmitter that can contribute to dyskinesias. Dopamine agonists such as pramipexole and ropinirole mimic the effects of dopamine in the brain and can help reduce dyskinesias by reducing the dose of levodopa required for symptom control.
It is important to note that anti-dyskinetic agents may have side effects, and their use should be carefully monitored by a healthcare provider.
Aprindine is a class IA antiarrhythmic agent, which is primarily used to treat cardiac arrhythmias (abnormal heart rhythms). It works by blocking sodium channels in the heart muscle cells, which helps to stabilize the heart's electrical activity and restore normal rhythm.
The medical definition of Aprindine can be stated as:
"Aprindine is a sodium channel blocker that is used in the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. It works by slowing down the conduction of electrical impulses through the heart muscle cells, which helps to restore normal rhythm."
It is important to note that Aprindine can have serious side effects, including increased risk of ventricular arrhythmias and cardiac arrest, especially when used in high doses or in patients with certain underlying medical conditions. Therefore, it should only be prescribed by a healthcare professional who has experience in managing cardiac arrhythmias.
Phenmetrazine is a stimulant drug that was previously used for the treatment of obesity, but its use has been discontinued in many countries due to its addictive potential and adverse effects. It acts as a central nervous system stimulant, increasing heart rate, blood pressure, and alertness, and decreasing appetite.
The medical definition of Phenmetrazine is:
A psychostimulant drug that has been used in the treatment of obesity but has been discontinued in many countries due to its addictive potential and adverse effects. It is a phenylpropylamine derivative, structurally related to amphetamine and methamphetamine, and acts as a central nervous system stimulant, increasing heart rate, blood pressure, and alertness, and decreasing appetite. Phenmetrazine has sympathomimetic effects, releasing catecholamines from presynaptic nerve endings and blocking their reuptake, resulting in increased concentrations of these neurotransmitters in the synaptic cleft. It also inhibits monoamine oxidase, further increasing the concentration of catecholamines in the brain.
Phenmetrazine is classified as a Schedule II controlled substance in the United States due to its high potential for abuse and dependence. Its use is limited to research purposes only and requires a special license from the Drug Enforcement Administration (DEA).
Basal ganglia diseases are a group of neurological disorders that affect the function of the basal ganglia, which are clusters of nerve cells located deep within the brain. The basal ganglia play a crucial role in controlling movement and coordination. When they are damaged or degenerate, it can result in various motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and difficulty with balance and walking.
Some examples of basal ganglia diseases include:
1. Parkinson's disease - a progressive disorder that affects movement due to the death of dopamine-producing cells in the basal ganglia.
2. Huntington's disease - an inherited neurodegenerative disorder that causes uncontrolled movements, emotional problems, and cognitive decline.
3. Dystonia - a movement disorder characterized by sustained or intermittent muscle contractions that cause twisting and repetitive movements or abnormal postures.
4. Wilson's disease - a rare genetic disorder that causes excessive copper accumulation in the liver and brain, leading to neurological and psychiatric symptoms.
5. Progressive supranuclear palsy (PSP) - a rare brain disorder that affects movement, gait, and balance, as well as speech and swallowing.
6. Corticobasal degeneration (CBD) - a rare neurological disorder characterized by progressive loss of nerve cells in the cerebral cortex and basal ganglia, leading to stiffness, rigidity, and difficulty with movement and coordination.
Treatment for basal ganglia diseases varies depending on the specific diagnosis and symptoms but may include medication, surgery, physical therapy, or a combination of these approaches.
Dopamine agonists are a class of medications that mimic the action of dopamine, a neurotransmitter in the brain that regulates movement, emotion, motivation, and reinforcement of rewarding behaviors. These medications bind to dopamine receptors in the brain and activate them, leading to an increase in dopaminergic activity.
Dopamine agonists are used primarily to treat Parkinson's disease, a neurological disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. By increasing dopaminergic activity in the brain, dopamine agonists can help alleviate some of these symptoms.
Examples of dopamine agonists include:
1. Pramipexole (Mirapex)
2. Ropinirole (Requip)
3. Rotigotine (Neupro)
4. Apomorphine (Apokyn)
Dopamine agonists may also be used off-label to treat other conditions, such as restless legs syndrome or certain types of dopamine-responsive dystonia. However, these medications can have significant side effects, including nausea, dizziness, orthostatic hypotension, compulsive behaviors (such as gambling, shopping, or sexual addiction), and hallucinations. Therefore, they should be used with caution and under the close supervision of a healthcare provider.
Neurotensin is a neuropeptide that is widely distributed in the central nervous system and the gastrointestinal tract. It is composed of 13 amino acids and plays a role as a neurotransmitter or neuromodulator in various physiological functions, including pain regulation, temperature regulation, and feeding behavior. Neurotensin also has been shown to have potential roles in the development of certain diseases such as cancer and neurological disorders. It exerts its effects by binding to specific receptors, known as neurotensin receptors (NTSR1, NTSR2, and NTSR3), which are widely distributed throughout the body.
Butyrophenones are a group of synthetic antipsychotic drugs that are primarily used to treat symptoms of schizophrenia and other psychotic disorders. They act as dopamine receptor antagonists, which means they block the action of dopamine, a neurotransmitter in the brain associated with mood, motivation, and pleasure.
Some examples of butyrophenones include haloperidol, droperidol, and benperidol. These drugs are known for their potent antipsychotic effects and can also be used to manage agitation, aggression, and other behavioral disturbances in patients with various psychiatric and neurological disorders.
In addition to their antipsychotic properties, butyrophenones have been used off-label for their sedative and analgesic effects. However, they are associated with a range of side effects, including extrapyramidal symptoms (EPS), such as involuntary muscle spasms and tremors, as well as other neurological and cardiovascular adverse reactions. Therefore, their use is typically reserved for cases where other treatments have been ineffective or contraindicated.
Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), which is the main psychoactive compound found in cannabis. It is approved by the US Food and Drug Administration (FDA) for the treatment of nausea and vomiting caused by chemotherapy in cancer patients, as well as to stimulate appetite and weight gain in patients with AIDS wasting syndrome.
Dronabinol is available in capsule form and is typically taken two to three times a day, depending on the prescribed dosage. It may take several days or even weeks of regular use before the full therapeutic effects are achieved.
Like cannabis, dronabinol can cause psychoactive effects such as euphoria, altered mood, and impaired cognitive function. Therefore, it is important to follow the prescribing instructions carefully and avoid driving or operating heavy machinery while taking this medication. Common side effects of dronabinol include dizziness, drowsiness, dry mouth, and difficulty with coordination.
'Animal behavior' refers to the actions or responses of animals to various stimuli, including their interactions with the environment and other individuals. It is the study of the actions of animals, whether they are instinctual, learned, or a combination of both. Animal behavior includes communication, mating, foraging, predator avoidance, and social organization, among other things. The scientific study of animal behavior is called ethology. This field seeks to understand the evolutionary basis for behaviors as well as their physiological and psychological mechanisms.
Neurotensin receptors are a type of G protein-coupled receptor (GPCR) that bind to the neuropeptide neurotensin. Neurotensin is a endogenous neuropeptide that is widely distributed in both the central and peripheral nervous systems, where it functions as a neurotransmitter or neuromodulator.
There are three subtypes of neurotensin receptors, NTS1, NTS2, and NTS3 (also known as sortilin), each with different binding affinities for neurotensin and distinct signaling properties.
NTS1 is a high-affinity receptor that is widely expressed in the brain and activates several intracellular signaling pathways, including the MAPK/ERK pathway, PI3K/Akt pathway, and the release of calcium ions from intracellular stores. NTS1 has been implicated in a variety of physiological functions, such as pain modulation, feeding behavior, and reward processing.
NTS2 is a low-affinity receptor that is predominantly expressed in the peripheral nervous system and activates different signaling pathways than NTS1, including the activation of phospholipase C and the release of intracellular calcium ions. NTS2 has been implicated in the regulation of gastrointestinal motility and secretion.
NTS3 is a sorting receptor that is involved in the intracellular trafficking of neurotensin and other ligands, but its role as a signaling receptor is less well understood.
Overall, neurotensin receptors play important roles in various physiological processes, and their dysregulation has been implicated in several pathological conditions, such as pain disorders, drug addiction, and gastrointestinal diseases.
"Maternal-Fetal Relations" is not a standard medical term. However, I believe you may be asking for a definition of "Maternal-Fetal Medicine," which is a subspecialty of obstetrics that focuses on the care of pregnant women with high-risk pregnancies and their unborn babies. Maternal-Fetal Medicine specialists provide comprehensive care to these patients, including consultation, diagnosis, treatment, and management of medical complications during pregnancy that may affect the mother, fetus, or both. They work closely with obstetricians, perinatologists, geneticists, and other healthcare professionals to optimize outcomes for both the mother and the baby.
Raclopride is not a medical condition but a drug that belongs to the class of dopamine receptor antagonists. It's primarily used in research and diagnostic settings as a radioligand in positron emission tomography (PET) scans to visualize and measure the distribution and availability of dopamine D2 and D3 receptors in the brain.
In simpler terms, Raclopride is a compound that can be labeled with a radioactive isotope and then introduced into the body to track the interaction between the radioligand and specific receptors (in this case, dopamine D2 and D3 receptors) in the brain. This information can help researchers and clinicians better understand neurochemical processes and disorders related to dopamine dysfunction, such as Parkinson's disease, schizophrenia, and drug addiction.
It is important to note that Raclopride is not used as a therapeutic agent in clinical practice due to its short half-life and the potential for side effects associated with dopamine receptor blockade.
Serotonin 5-HT1 receptor antagonists are a class of pharmaceutical drugs that block the activation of serotonin 5-HT1 receptors. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter that plays a role in various physiological functions, including mood regulation, appetite control, and sensory perception. The 5-HT1 receptor family includes several subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that are widely distributed throughout the central and peripheral nervous systems.
When serotonin binds to these receptors, it triggers a series of intracellular signaling events that can have excitatory or inhibitory effects on neuronal activity. By blocking the interaction between serotonin and 5-HT1 receptors, antagonists modulate the downstream consequences of receptor activation.
Serotonin 5-HT1 receptor antagonists are used in various clinical contexts to treat or manage a range of conditions:
1. Migraine prevention: Some 5-HT1B/1D receptor antagonists, such as sumatriptan and rizatriptan, are highly effective in aborting migraine attacks by constricting dilated cranial blood vessels and reducing the release of pro-inflammatory neuropeptides.
2. Nausea and vomiting: Certain 5-HT3 receptor antagonists, like ondansetron and granisetron, are used to prevent chemotherapy-induced nausea and vomiting by blocking the activation of emetic circuits in the brainstem.
3. Psychiatric disorders: Although not widely used, some 5-HT1A receptor antagonists have shown promise in treating depression and anxiety disorders due to their ability to modulate serotonergic neurotransmission.
4. Neuroprotection: Preclinical studies suggest that 5-HT1A receptor agonists may have neuroprotective effects in various neurological conditions, such as Parkinson's disease and stroke. However, further research is needed to establish their clinical utility.
In summary, serotonin 5-HT1 receptor antagonists are a diverse group of medications with applications in migraine prevention, nausea and vomiting management, psychiatric disorders, and potential neuroprotection. Their unique pharmacological profiles enable them to target specific pathophysiological mechanisms underlying various conditions, making them valuable tools in modern therapeutics.
Catalepsy
Catalepsy (band)
Catatonia
Adolphe Wahltuch
Central nervous system disease
Mat Bruso
Confesiones de Invierno
2011 in heavy metal music
Tonipet Gaba
Demon
Tetrad test
UWA-101
Hallucinogen
The Comedy of Terrors
Ghilianella borincana
La traición (2008 TV series)
Melanocyte-inhibiting factor
5-HT2B receptor
SB-215505
Posthypnotic amnesia
Martha Hatfield
Waxy flexibility
SB-228357
Potion
Babalú-Ayé
Détente (band)
Henry Byng, 4th Earl of Strafford
Potters Bar rail accidents
Clitoridectomy
Eurycantha calcarata
Catalepsy - Wikipedia
Catalepsis [ CATALEPSIS, ] :: Search the 1828 Noah Webster's Dictionary of the English Language (FREE) :: 1828.mshaffer.com
Catalepsy - McMaster Experts
Catalepsy | Martyr Hardcore Metal Online Store
Catalepsy, Memory and Suggestion in Psyc, 9780367254162
Catalepsy - 'Bleed' OFFICIAL MUSIC VIDEO - VIDEO | BANDMINE.COM
Catalepsy, Memory and Suggestion in Psychological Automatism - The Brainary
Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlorodiazepoxide<...
Drawings of a woman in catalepsy by Albert Londe-1024×557 - eStudio 131
Atropine acts in the ventral striatum to reduce raclopride-induced catalepsy<...
incessancy Rhymes | Encyclopedia.com
Unlock the Power of Arm Catalepsy with Our Hypnosis Download - Hypnosis Downloads | Hypnosis Scripts | Mp3
Antinociceptive Activity of Trichilia catigua Hydroalcoholic Extract: New Evidence on Its Dopaminergic Effects
Catatonia: Practice Essentials, Background, Pathophysiology and Etiology
Poe's Short Stories: "The Fall of the House of Usher" (1839) Quiz: Quick Quiz | SparkNotes
Catatonic Depression: All You Need to Know I Psych Central
Bush-Francis Catatonia Rating Scale -Collaborative Care and Wellness - Our Divisions - Department of Psychiatry - University of...
Hypnotherapist Courses | Hypnosis Downloads
Mood Disorder
Project Gutenberg's Buchanan's Journal of Man, July 1887, by Various
Robert DuPont as shill for the drug testing industry | Drug WarRant
Wordnik: Manji's Random Wordlist
Course Syllabus | Hypnotherapy Training | Hypnotic World
Erowid.org: References Database
Browse Wordsmyth dictionary online as if using a print book | Wordsmyth
The Fall of the House of Usher by Edgar Allan Poe
I Say Unto You Vol 2 05 - Osho World
Haloperidol-induced catalepsy1
- The possible involvement of the dopaminergic system in the actions of T. catigua extract was substantiated by data showing the potentiation of apomorphine-induced hypothermia and by the prevention of haloperidol-induced catalepsy. (hindawi.com)
Posturing1
- Catalepsy is a more severe type of posturing where the posturing occurs passively, not on purpose. (psychcentral.com)
Stupor1
- George Eliot Silas Marner In William Shakespeare's tragedy Romeo and Juliet, the kindly Friar Laurence (in the course of a botched attempt to help the lovers) provides Juliet with a catalepsy-inducing potion so effective that Romeo tragically imagines his beloved's deathlike trance to be actual death and poisons himself in despair just before she awakens from her stupor-leading her to kill herself with his dagger upon discovering his suicide. (wikipedia.org)
Rats1
- Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? (erowid.org)
Spontaneous1
- Unsuggested waxy catalepsy, sometimes accompanied by spontaneous anesthesia, is seen as an indicator of hypnotic trance. (wikipedia.org)
Rigid3
- Suggested or induced rigid catalepsy, of extended limbs or even the entire body, sometimes tested with heavy weights, has been a staple of stage hypnosis shows and even academic demonstrations of hypnotism since the late 18th century, as proof of extraordinary physical abilities possible in trance states. (wikipedia.org)
- Arm catalepsy is a state of deep relaxation where your arm becomes completely rigid and unmoving, as if it were made of stone. (ehypnosisdownloads.com)
- Catalepsy is an abnormal nervous condition in which the face, limbs, and body lose their voluntary motion and become rigid for what may be several hours. (funtrivia.com)
Epilepsy1
- Catalepsy is a symptom of certain nervous disorders or conditions such as Parkinson's disease and epilepsy. (wikipedia.org)
Nervous1
- Catalepsy (from Ancient Greek katálēpsis, κατάληψις, "seizing, grasping") is a nervous condition characterized by muscular rigidity and fixity of posture regardless of external stimuli, as well as decreased sensitivity to pain. (wikipedia.org)
Time2
- In Alexandre Dumas, père's novel The Count of Monte Cristo, the Abbé Faria has fits of catalepsy from time to time, before eventually dying from one. (wikipedia.org)
- The number of animals displaying catalepsy (50%) and mean total catalepsy time (11,92 ± 4,12 minutes) were lower in sleep deprived animals than in controls (91.7% and 26.67 ± 5.86 min respectively), results being statistically significant at the limit level (p=0,05). (bvsalud.org)
Condition1
- Armand D'Angour suggests that reports (such as that recounted in Plato's Symposium) of Socrates, in about 429 BC, standing perfectly still for hours on end during the Athenian campaign against Potidaea while seemingly deep in thought, are 'too extreme to be considered wholly a matter of rational choice,' and that 'it is reasonable to suppose that it was the symptom of an underlying physiological or psychological condition', such as catalepsy. (wikipedia.org)
State2
- By simply listening to our soothing audio, you will effortlessly enter a state of deep relaxation, paving the way for arm catalepsy to take over. (ehypnosisdownloads.com)
- Catalepsis: a suspended state of trance-like immobility. (frameworkradio.net)
Effect2
- In the arts, catalepsy is often used for dramatic effect, sometimes as a plot device. (wikipedia.org)
- The present study evaluated the effect of REM-sleep deprivation on the catalepsy induced by lactate administration plus forced muscular activity. (bvsalud.org)
Body1
- Welcome to the enchanting world of arm catalepsy, where your mind and body intertwine to create an experience like no other. (ehypnosisdownloads.com)
Long1
- It is concluded that in long lasting dangerous situations, catalepsy may be triggered after normal wakefulness coping possibilities are exhausted, and sleep being manifested only when the risk situation is over. (bvsalud.org)
World1
- During this hypnosis session, arm catalepsy will become your doorway to a world of endless possibilities. (ehypnosisdownloads.com)
Full1
- By listening to our hypnosis download on a regular basis, you will gradually unleash the full potential of arm catalepsy within you. (ehypnosisdownloads.com)
Analgesia1
- In the cannabinoid tetrad pharmacological test, Δ 9 -THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity. (nature.com)
Trance3
- Unsuggested waxy catalepsy, sometimes accompanied by spontaneous anesthesia, is seen as an indicator of hypnotic trance. (wikipedia.org)
- Suggested or induced rigid catalepsy, of extended limbs or even the entire body, sometimes tested with heavy weights, has been a staple of stage hypnosis shows and even academic demonstrations of hypnotism since the late 18th century, as proof of extraordinary physical abilities possible in trance states. (wikipedia.org)
- George Eliot Silas Marner In William Shakespeare's tragedy Romeo and Juliet, the kindly Friar Laurence (in the course of a botched attempt to help the lovers) provides Juliet with a catalepsy-inducing potion so effective that Romeo tragically imagines his beloved's deathlike trance to be actual death and poisons himself in despair just before she awakens from her stupor-leading her to kill herself with his dagger upon discovering his suicide. (wikipedia.org)
Mice8
- Behavioral effects of classic antidepressants, fluoxetine and imipramine, and new psychotropic benzopentathiepin TC-2153 (20 mg/kg, per os) were studied on mice differing in the predisposition to catalepsy-noncataleptic AKR strain and cataleptic strains CBA and AKR.CBA-D13Mit76 (D13). (nih.gov)
- Mice of D13 strain was created by transferring the CBA-allele of major locus of catalepsy to AKR genome. (nih.gov)
- Spatial learning in the Morris water maze in mice genetically different in the predisposition to catalepsy: the effect of intraventricular treatment with brain-derived neurotrophic factor. (nih.gov)
- Eight halogenated derivatives of cannabinol (CBN) substituted on the aromatic ring at the 2 and/or 4 position were synthesized and their pharmacological effects were evaluated by intracerebroventricular injection (50 micrograms/mouse) in mice, using hypothermia, pentobarbital-induced sleep prolongation, catalepsy and anticonvulsant effect as indices. (nih.gov)
- The effects of AZE in apomorphine-induced cage climbing test, extract-induced catalepsy, and haloperidol-induced catalepsy on mice were also investigated. (hindawi.com)
- AZE, while failing to produce any cataleptic event in naïve mice, significantly enhanced haloperidol-induced catalepsy at a dose of 1000 mg/kg. (hindawi.com)
- 7. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. (nih.gov)
- 17. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. (nih.gov)
Ecstasy1
- Erowid.org: Erowid Reference 6165 : Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? (erowid.org)
Catatonic1
- Raphael is prone to sometimes long bouts of catalepsy, in which he enters essentially a catatonic state. (buber.net)